202 related articles for article (PubMed ID: 25173966)
1. Role of calreticulin mutations in the aetiological diagnosis of splanchnic vein thrombosis.
Turon F; Cervantes F; Colomer D; Baiges A; Hernández-Gea V; Garcia-Pagán JC
J Hepatol; 2015 Jan; 62(1):72-4. PubMed ID: 25173966
[TBL] [Abstract][Full Text] [Related]
2. Prevalence of CALR mutations in splanchnic vein thrombosis: A systematic review and meta-analysis.
Li M; De Stefano V; Song T; Zhou X; Guo Z; Zhu J; Qi X
Thromb Res; 2018 Jul; 167():96-103. PubMed ID: 29803161
[TBL] [Abstract][Full Text] [Related]
3. Next-generation sequencing in the diagnosis of non-cirrhotic splanchnic vein thrombosis.
Magaz M; Alvarez-Larrán A; Colomer D; López-Guerra M; García-Criado MÁ; Mezzano G; Belmonte E; Olivas P; Soy G; Cervantes F; Darnell A; Ferrusquía-Acosta J; Baiges A; Turon F; Hernández-Gea V; García-Pagán JC
J Hepatol; 2021 Jan; 74(1):89-95. PubMed ID: 32679300
[TBL] [Abstract][Full Text] [Related]
4. Selective testing for calreticulin gene mutations in patients with splanchnic vein thrombosis: A prospective cohort study.
Poisson J; Plessier A; Kiladjian JJ; Turon F; Cassinat B; Andreoli A; De Raucourt E; Goria O; Zekrini K; Bureau C; Lorre F; Cervantes F; Colomer D; Durand F; Garcia-Pagan JC; Casadevall N; Valla DC; Rautou PE; Marzac C;
J Hepatol; 2017 Sep; 67(3):501-507. PubMed ID: 28483676
[TBL] [Abstract][Full Text] [Related]
5. Splanchnic vein thrombosis and myeloproliferative neoplasms: molecular-driven diagnosis and long-term treatment.
De Stefano V; Qi X; Betti S; Rossi E
Thromb Haemost; 2016 Jan; 115(2):240-9. PubMed ID: 26333846
[TBL] [Abstract][Full Text] [Related]
6. The molecular landscape of myeloproliferative neoplasms associated with splanchnic vein thrombosis: Current perspective.
Pescia C; Lopez G; Cattaneo D; Bucelli C; Gianelli U; Iurlo A
Leuk Res; 2024 Jan; 136():107420. PubMed ID: 38016412
[TBL] [Abstract][Full Text] [Related]
7. The clinical significance of JAK2V617F mutation for Philadelphia-negative chronic myeloproliferative neoplasms in patients with splanchnic vein thrombosis.
Yonal I; Pinarbası B; Hindilerden F; Hancer VS; Nalcaci M; Kaymakoglu S; Diz-Kucukkaya R
J Thromb Thrombolysis; 2012 Oct; 34(3):388-96. PubMed ID: 22569900
[TBL] [Abstract][Full Text] [Related]
8. Prevalence of prothrombotic factors in patients with Budd-Chiari syndrome or non-cirrhotic nonmalignant portal vein thrombosis: A hospital-based observational study.
Fan J; Wang Q; Luo B; Chen H; Wang Z; Niu J; Yuan J; Yuan X; Bai W; He C; Guo W; Li K; Yin Z; Fan D; Han G
J Gastroenterol Hepatol; 2020 Jul; 35(7):1215-1222. PubMed ID: 31711259
[TBL] [Abstract][Full Text] [Related]
9. Myeloproliferative neoplasms in Budd-Chiari syndrome and portal vein thrombosis: a meta-analysis.
Smalberg JH; Arends LR; Valla DC; Kiladjian JJ; Janssen HL; Leebeek FW
Blood; 2012 Dec; 120(25):4921-8. PubMed ID: 23043069
[TBL] [Abstract][Full Text] [Related]
10. CALR, JAK2, and MPL mutation profiles in patients with four different subtypes of myeloproliferative neoplasms: primary myelofibrosis, essential thrombocythemia, polycythemia vera, and myeloproliferative neoplasm, unclassifiable.
Kim SY; Im K; Park SN; Kwon J; Kim JA; Lee DS
Am J Clin Pathol; 2015 May; 143(5):635-44. PubMed ID: 25873496
[TBL] [Abstract][Full Text] [Related]
11. Simultaneous screening for JAK2 and calreticulin gene mutations in myeloproliferative neoplasms with high resolution melting.
Matsumoto N; Mori S; Hasegawa H; Sasaki D; Mori H; Tsuruda K; Imanishi D; Imaizumi Y; Hata T; Kaku N; Kosai K; Uno N; Miyazaki Y; Yanagihara K
Clin Chim Acta; 2016 Nov; 462():166-173. PubMed ID: 27693531
[TBL] [Abstract][Full Text] [Related]
12. Validation of a molecular diagnostic assay for CALR exon 9 indels in myeloproliferative neoplasms: identification of coexisting JAK2 and CALR mutations and a novel 9 bp deletion in CALR.
Murugesan G; Guenther-Johnson J; Mularo F; Cook JR; Daly TM
Int J Lab Hematol; 2016 Jun; 38(3):284-97. PubMed ID: 27018326
[TBL] [Abstract][Full Text] [Related]
13. Splanchnic vein thrombosis in myeloproliferative neoplasms: pathophysiology and molecular mechanisms of disease.
How J; Zhou A; Oh ST
Ther Adv Hematol; 2017 Mar; 8(3):107-118. PubMed ID: 28246554
[TBL] [Abstract][Full Text] [Related]
14. Coexisting JAK2V617F and CALR Exon 9 Mutations in Myeloproliferative Neoplasms - Do They Designate a New Subtype?
Ahmed RZ; Rashid M; Ahmed N; Nadeem M; Shamsi TS
Asian Pac J Cancer Prev; 2016; 17(3):923-6. PubMed ID: 27039813
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic value of the JAK2 V617F mutation for latent chronic myeloproliferative disorders in patients with Budd-Chiari syndrome and/or portal vein thrombosis.
Karaköse S; Oruç N; Zengin M; Akarca US; Ersöz G
Turk J Gastroenterol; 2015 Jan; 26(1):42-8. PubMed ID: 25698270
[TBL] [Abstract][Full Text] [Related]
16. Development of a Targeted Next-Generation Sequencing Assay to Detect Diagnostically Relevant Mutations of JAK2, CALR, and MPL in Myeloproliferative Neoplasms.
Frawley T; O'Brien CP; Conneally E; Vandenberghe E; Percy M; Langabeer SE; Haslam K
Genet Test Mol Biomarkers; 2018 Feb; 22(2):98-103. PubMed ID: 29323541
[TBL] [Abstract][Full Text] [Related]
17. Pathological and genomic features of myeloproliferative neoplasms associated with splanchnic vein thrombosis in a single-center cohort.
Cattaneo D; Bucelli C; Marchetti A; Lionetti M; Fermo E; Bellani V; De Magistris C; Maeda A; Marella A; Primignani M; Consonni D; Gianelli U; Neri A; Baldini L; Bolli N; Iurlo A
Ann Hematol; 2023 Jun; 102(6):1409-1420. PubMed ID: 37079068
[TBL] [Abstract][Full Text] [Related]
18. JAK2V617F mutation prevalence on Chilean adults suffering from primary mesenteric and portal venous thromboses.
González-Montero J; Del Valle-Batalla L; Castillo-Astorga R; Marín Valdés A; Conte Lanza G
Int J Lab Hematol; 2020 Jun; 42(3):331-334. PubMed ID: 32154655
[TBL] [Abstract][Full Text] [Related]
19. Prevalence and phenotypes of
Cordua S; Kjaer L; Skov V; Pallisgaard N; Hasselbalch HC; Ellervik C
Blood; 2019 Aug; 134(5):469-479. PubMed ID: 31217187
[TBL] [Abstract][Full Text] [Related]
20. Somatic mutations of calreticulin in myeloproliferative neoplasms.
Klampfl T; Gisslinger H; Harutyunyan AS; Nivarthi H; Rumi E; Milosevic JD; Them NC; Berg T; Gisslinger B; Pietra D; Chen D; Vladimer GI; Bagienski K; Milanesi C; Casetti IC; Sant'Antonio E; Ferretti V; Elena C; Schischlik F; Cleary C; Six M; Schalling M; Schönegger A; Bock C; Malcovati L; Pascutto C; Superti-Furga G; Cazzola M; Kralovics R
N Engl J Med; 2013 Dec; 369(25):2379-90. PubMed ID: 24325356
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]